Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press47010.17650/1994-4098-2016-12-1-12-18MAMMOLOGY. TOPICAL ISSUEМАММОЛОГИЯ. АКТУАЛЬНАЯ ТЕМАTreatment of patients with bone marrow metastases: the present state of the problemСовременное состояние проблемы лечения пациенток с микрометастазами в костном мозгеKozlovskayaS. P.КозловскаяС. П.
Russian Federation
sve3110@rambler.ruAntonenkovaN. N.АнтоненковаН. Н.
Russian Federation
ZhavridE. A.ЖавридЭ. А.
Russian Federation
N.N. Aleksandrov Republican Research and Practical Center for Oncology and Medical RadiologyГУ «Республиканский научно-практический центр онкологии и медицинской радиологии им. Н. Н. Александрова»Lesnoy Agrotown, Minsk Region, 223040, Republic of BelarusРеспублика Беларусь, 223040, Минский р-н, агрогородок Лесной0606201612112180606201606062016https://ojrs.abvpress.ru/ojrs/article/view/470

The paper reviews the data available in the literature on the identification of tumor cells in bone marrow and peripheral blood in different tumors and breast cancer. Analysis of the majority of investigations suggest that the presence of tumor cells in the bone marrow correlates with early disease recurrences and lower survival; to detect bone marrow tumor cells is one of the most important approaches to early identifying metastases and improving the results of treatment for breast cancer. The paper gives the results of an investigation conducted at the N.N. Aleksandrov Republican Research and Practical Center for Oncology and Medical Radiology in 2008 to 2014, which established that the presence of cancer cells in the bone marrow is a poor prognostic sign: the 3-year relapse-free survival of patients with the unaffected and affected bone marrow was 88.7 and 69.3 %, respectively (p < 0.01).

Представлен обзор данных литературы, посвященный определению опухолевых клеток в костном мозге и периферической крови при различных опухолевых заболеваниях, а также при раке молочной железы. Анализ большинства исследований свидетельствует о том, что наличие опухолевых клеток в костном мозге коррелирует с ранними рецидивами заболевания и меньшей продолжительностью жизни; определение опухолевых клеток в костном мозге является одним из важнейших подходов для раннего выявления метастазов и улучшения результатов лечения рака молочной железы. Представлены результаты исследования, проведенного в РНПЦ онкологии и медицинской радиологии им. Н. Н. Александрова с 2008 по 2014 г., в ходе которого установлено, что наличие раковых клеток в костном мозге является неблагоприятным прогностическим признаком: 3-летняя безрецидивная выживаемость пациенток с непораженным костным мозгом составляет 88,7 %, с пораженным костным мозгом – 69,3 % (р < 0,01).

breast cancermicrometastasestumor cells in bone marrowpolymerase chain reactionрак молочной железымикрометастазыопухолевые клетки в костном мозгеполимеразная цепная реакция1. Океанов А.Е., Моисеев П.И., Левин Л.Ф. Статистика онкологических заболеваний. Под ред. О.Г. Суконко. Минск: РНПЦ ОМР им. Н.Н. Александрова, 2014. С. 136–41. [Оkeanov А.Е., Моiseev P.I., Levin L.F. Statistics of oncologic diseases. Ed. by О.G. Sukonkо. Мinsk: N.N. Aleksandrov RSPC OMR, 2014. Pp. 136–41. (In Russ.)].Океанов А.Е., Моисеев П.И., Левин Л.Ф. Статистика онкологических заболеваний. Под ред. О.Г. Суконко. Минск: РНПЦ ОМР им. Н.Н. Александрова, 2014. С. 136–41. [Оkeanov А.Е., Моiseev P.I., Levin L.F. Statistics of oncologic diseases. Ed. by О.G. Sukonkо. Мinsk: N.N. Aleksandrov RSPC OMR, 2014. Pp. 136–41. (In Russ.)].2. Стенина М.Б. Опухоли женской репродуктивной сферы. Рак молочной железы. В кн.: Руководство по химиотерапии опухолевых заболеваний. Под ред. Н.И. Переводчиковой, В.А. Горбуновой. М.: Практическая медицина, 2015. С. 241–57. [Steninа М.B. Tumors of the female reproductive system. Mammary gland cancer. In: Manual for the chemotherapy of tumor diseases. Ed. by N.I. Perevodchikova, V.А. Gorbunova. Мoscow: Prakticheskaya Meditsina, 2015. Pp. 241–57. (In Russ.)].Стенина М.Б. Опухоли женской репродуктивной сферы. Рак молочной железы. В кн.: Руководство по химиотерапии опухолевых заболеваний. Под ред. Н.И. Переводчиковой, В.А. Горбуновой. М.: Практическая медицина, 2015. С. 241–57. [Steninа М.B. Tumors of the female reproductive system. Mammary gland cancer. In: Manual for the chemotherapy of tumor diseases. Ed. by N.I. Perevodchikova, V.А. Gorbunova. Мoscow: Prakticheskaya Meditsina, 2015. Pp. 241–57. (In Russ.)].3. Riethdorf S., Pantel K. Disseminated tumor cells in bone marrow and circulating tumor cells in blood of breast cancer patients: current state of detection and characterization. Pathobiology 2008;75(2):140–8.Riethdorf S., Pantel K. Disseminated tumor cells in bone marrow and circulating tumor cells in blood of breast cancer patients: current state of detection and characterization. Pathobiology 2008;75(2):140–8.4. Braun S., Vogl F.D., Naume B. et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005;353(8):793–802.Braun S., Vogl F.D., Naume B. et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005;353(8):793–802.5. Janni W., Rack B., Schindlbeck C. et al. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer 2005;103(5): 884–91.Janni W., Rack B., Schindlbeck C. et al. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer 2005;103(5): 884–91.6. Schoenfeld A., Kruger K.H., Gomm J. et al. The detection of micrometastases in the peripheral blood and bone marrow of patients with breast cancer using immunohistochemistry and reverse transcriptase polymerase chain reaction for keratin 19. Eur J Cancer 1997;33(6):854–61.Schoenfeld A., Kruger K.H., Gomm J. et al. The detection of micrometastases in the peripheral blood and bone marrow of patients with breast cancer using immunohistochemistry and reverse transcriptase polymerase chain reaction for keratin 19. Eur J Cancer 1997;33(6):854–61.7. Kim M.Y., Oskarsson T., Acharyya S. et al. Tumor self-seeding by circulating cancer cells. Cell 2009;139(7):1315–26.Kim M.Y., Oskarsson T., Acharyya S. et al. Tumor self-seeding by circulating cancer cells. Cell 2009;139(7):1315–26.8. Стариков В.И., Ходак А.С. Детекция диссеминированных опухолевых клеток в крови, костном мозге и лимфатических узлах с помощью молекулярно-биологических методов. Международный медицинский журнал 2007;(2):96–100. [Starikov V.I., Khodak А.S. Detection of disseminated tumor cells in blood, bone marrow and lymphatic nodules by means of molecular and biologic methods. Mezhdunarodnyy meditsinskiy zhurnal = International Medical Journal 2007;(2):96–100. (In Russ.)].Стариков В.И., Ходак А.С. Детекция диссеминированных опухолевых клеток в крови, костном мозге и лимфатических узлах с помощью молекулярно-биологических методов. Международный медицинский журнал 2007;(2):96–100. [Starikov V.I., Khodak А.S. Detection of disseminated tumor cells in blood, bone marrow and lymphatic nodules by means of molecular and biologic methods. Mezhdunarodnyy meditsinskiy zhurnal = International Medical Journal 2007;(2):96–100. (In Russ.)].9. Смолякова Р.М. и др. Молекулярно-генетические исследования в клинической онкологии. В кн.: Руководство по онкологии. В 2 т. Под общ. ред. О.Г. Суконко. Минск: Беларус. энцикл. им. П. Бровки, 2015. Т. 1. С. 356–60. [Smolyakovа R.М. et al. Molecular and genetic studies in clinical oncology. In: Oncology manual. In 2 vol. General ed. by О.G. Sukonkо. Мinsk: Belarus. encycl. im. P. Brovki, 2015. Vol. 1. Pp. 356–60. (In Russ.)].Смолякова Р.М. и др. Молекулярно-генетические исследования в клинической онкологии. В кн.: Руководство по онкологии. В 2 т. Под общ. ред. О.Г. Суконко. Минск: Беларус. энцикл. им. П. Бровки, 2015. Т. 1. С. 356–60. [Smolyakovа R.М. et al. Molecular and genetic studies in clinical oncology. In: Oncology manual. In 2 vol. General ed. by О.G. Sukonkо. Мinsk: Belarus. encycl. im. P. Brovki, 2015. Vol. 1. Pp. 356–60. (In Russ.)].10. Braun S., Pantel K., Müller P. et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000;342(8): 525–33.Braun S., Pantel K., Müller P. et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000;342(8): 525–33.11. Nissan A., Jager D., Roystacher M. et al. Multimarker RT-PCR assay for the detection of minimal residual disease in sentinel lymph nodes of breast cancer patients. Br J Cancer 2006;94(5):681–5.Nissan A., Jager D., Roystacher M. et al. Multimarker RT-PCR assay for the detection of minimal residual disease in sentinel lymph nodes of breast cancer patients. Br J Cancer 2006;94(5):681–5.12. Chen Y., Zou T.N., Wu Z.P. et al. Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigenpositive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer. Int J Biol Markers 2010;25(2):59–68.Chen Y., Zou T.N., Wu Z.P. et al. Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigenpositive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer. Int J Biol Markers 2010;25(2):59–68.13. Szoke J., Udvarhelyi N. Modern pathologic diagnostics in breast cancer. Orv Hetil 2012;153(1):22–30.Szoke J., Udvarhelyi N. Modern pathologic diagnostics in breast cancer. Orv Hetil 2012;153(1):22–30.14. Mari P., Ozreti P., Levanat S. et al. Tumor markers in breast cancer – evaluation of their clinical usefulness. Coll Antropol 2011;35(1):241–7.Mari P., Ozreti P., Levanat S. et al. Tumor markers in breast cancer – evaluation of their clinical usefulness. Coll Antropol 2011;35(1):241–7.15. Weinschenker P., Soares H.P., Clark O., Del Giglio A. Immunocytochemical detection of epithelial cells in the bone marrow of primary breast cancer patients: a meta-analysis. Breast Cancer Res Treat 2004;87(3):215–24.Weinschenker P., Soares H.P., Clark O., Del Giglio A. Immunocytochemical detection of epithelial cells in the bone marrow of primary breast cancer patients: a meta-analysis. Breast Cancer Res Treat 2004;87(3):215–24.16. Al-Joudi F.S., Kaid F.A., Ishak I. et al. Expression of human mammaglobin and clinicopathologic correlations in breast cancer: findings in Malaysia. Indian J Pathol Microbiol 2011;54(2):284–9.Al-Joudi F.S., Kaid F.A., Ishak I. et al. Expression of human mammaglobin and clinicopathologic correlations in breast cancer: findings in Malaysia. Indian J Pathol Microbiol 2011;54(2):284–9.17. Al-Joudi F.S. Human mammaglobin in breast cancer: a brief review of its clinical utility. Indian J Med Res 2014;139(5):675–85.Al-Joudi F.S. Human mammaglobin in breast cancer: a brief review of its clinical utility. Indian J Med Res 2014;139(5):675–85.18. Koh E.H., Cho Y.W., Mun Y.J. et al. Upregulation of human mammaglobin reduces migration and invasion of breast cancer cells. Cancer Invest 2014;32(1):22–9.Koh E.H., Cho Y.W., Mun Y.J. et al. Upregulation of human mammaglobin reduces migration and invasion of breast cancer cells. Cancer Invest 2014;32(1):22–9.19. Lewis G.H., Subhawong A.P., Nassar H. et al. Relationship between molecular subtype of invasive breast carcinoma and expression of gross cystic disease fluid protein 15 and mammaglobin. Am J Clin Pathol 2011;135(4):587–91.Lewis G.H., Subhawong A.P., Nassar H. et al. Relationship between molecular subtype of invasive breast carcinoma and expression of gross cystic disease fluid protein 15 and mammaglobin. Am J Clin Pathol 2011;135(4):587–91.20. Li G., Zhang J., Jin K. et al. Human mammaglobin: a superior marker for reversetranscriptase PCR in detecting circulating tumor cells in breast cancer patients. Biomark Med 2011;5(2):249–60.Li G., Zhang J., Jin K. et al. Human mammaglobin: a superior marker for reversetranscriptase PCR in detecting circulating tumor cells in breast cancer patients. Biomark Med 2011;5(2):249–60.21. Ferro P., Franceschini M.C., Bacigalupo B. et al. Detection of circulating tumour cells in breast cancer patients using human mammaglobin RT-PCR: association with clinical prognostic factors. Anticancer Res 2010;30(6):2377–82.Ferro P., Franceschini M.C., Bacigalupo B. et al. Detection of circulating tumour cells in breast cancer patients using human mammaglobin RT-PCR: association with clinical prognostic factors. Anticancer Res 2010;30(6):2377–82.22. Dono M., Ferro P., Franceschini M.C. et al. Human mammaglobin transcript amplification for differential diagnosis in a breast cancer metastatic to dura mater. Anticancer Res 2011;31(3):1061–4.Dono M., Ferro P., Franceschini M.C. et al. Human mammaglobin transcript amplification for differential diagnosis in a breast cancer metastatic to dura mater. Anticancer Res 2011;31(3):1061–4.23. Wang Z., Spaulding B., Sienko A. et al. Mammaglobin, a valuable diagnostic marker for metastatic breast carcinoma. Int J Clin Exp Pathol 2009;2(4):384–9.Wang Z., Spaulding B., Sienko A. et al. Mammaglobin, a valuable diagnostic marker for metastatic breast carcinoma. Int J Clin Exp Pathol 2009;2(4):384–9.24. Markou A., Strati A., Malamos N. et al. Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization assay. Clin Chem 2011;57(3):421–30.Markou A., Strati A., Malamos N. et al. Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization assay. Clin Chem 2011;57(3):421–30.25. Ceballos M.P., Zumoffen C., Massa E. et al. Detection of mammaglobin A in blood from breast cancer patients, before and after treatment, using a one-tube nested PCR protocol. Association with the absence of tumor estrogen receptors. Clin Biochem 2011;44(17–18):1429–33.Ceballos M.P., Zumoffen C., Massa E. et al. Detection of mammaglobin A in blood from breast cancer patients, before and after treatment, using a one-tube nested PCR protocol. Association with the absence of tumor estrogen receptors. Clin Biochem 2011;44(17–18):1429–33.26. Lopez-Bonet E., Pérez-Martínez M.C., Martin-Castillo B. et al. Diagnostic utility of mammaglobin and GCDFP-15 in the identification of primary neuroendocrine carcinomas of the breast. Breast Cancer Res Treat 2011;126(1):241–5.Lopez-Bonet E., Pérez-Martínez M.C., Martin-Castillo B. et al. Diagnostic utility of mammaglobin and GCDFP-15 in the identification of primary neuroendocrine carcinomas of the breast. Breast Cancer Res Treat 2011;126(1):241–5.27. Tjensvoll K., Gilje B., Oltedal S. et al. A small subgroup of operable breast cancer patients with poor prognosis identified by quantitative real-time RT-PCR detection of mammaglobin A and trefoil factor 1 mRNA expression in bone marrow. Breast Cancer Res Treat 2009;116(2):329–38.Tjensvoll K., Gilje B., Oltedal S. et al. A small subgroup of operable breast cancer patients with poor prognosis identified by quantitative real-time RT-PCR detection of mammaglobin A and trefoil factor 1 mRNA expression in bone marrow. Breast Cancer Res Treat 2009;116(2):329–38.28. Bitisik O., Saip P., Saglam S. et al. Mammaglobin and maspin transcripts in blood may reflect disease progression and the effect of therapy in breast cancer. Genet Mol Res 2010;9(1):97–106.Bitisik O., Saip P., Saglam S. et al. Mammaglobin and maspin transcripts in blood may reflect disease progression and the effect of therapy in breast cancer. Genet Mol Res 2010;9(1):97–106.29. Zuo L., Li L., Wang Q. et al. Mammaglobin as a potential molecular target for breast cancer drug delivery. Cancer Cell Int 2009;9:8.Zuo L., Li L., Wang Q. et al. Mammaglobin as a potential molecular target for breast cancer drug delivery. Cancer Cell Int 2009;9:8.30. Tiriveedhi V., Sarma N.J., Subramanian V. et al. Identification of HLA-A24-restricted CD8(+) cytotoxic T-cell epitopes derived from mammaglobin-A, a human breast cancerassociated antigen. Hum Immunol 2012;73(1):11–6.Tiriveedhi V., Sarma N.J., Subramanian V. et al. Identification of HLA-A24-restricted CD8(+) cytotoxic T-cell epitopes derived from mammaglobin-A, a human breast cancerassociated antigen. Hum Immunol 2012;73(1):11–6.31. Flatmark K., Borgen E., Nesland J.M. et al. Disseminated tumour cells as a prognostic biomarker in colorectal cancer. Br J Cancer 2011;104(9):1434–9.Flatmark K., Borgen E., Nesland J.M. et al. Disseminated tumour cells as a prognostic biomarker in colorectal cancer. Br J Cancer 2011;104(9):1434–9.32. Carpenter E.L., Rader J., Ruden J. et al. Dielectrophoretic capture and genetic analysis of single neuroblastoma tumor cells. Front Oncol 2014;4:201.Carpenter E.L., Rader J., Ruden J. et al. Dielectrophoretic capture and genetic analysis of single neuroblastoma tumor cells. Front Oncol 2014;4:201.33. Banys M., Solomayer E.F., Gebauer G. et al. Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial. BMC Cancer 2013;13:480–6.Banys M., Solomayer E.F., Gebauer G. et al. Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial. BMC Cancer 2013;13:480–6.34. Murray N.P., Reyes E., Tapia P. et al. Redefining micrometastasis in prostate cancer – a comparison of circulating prostate cells, bone marrow disseminated tumor cells and micrometastasis: Implications in determining local or systemic treatment for biochemical failure after radical prostatectomy. Int J Mol Med 2012;30(4): 896–904.Murray N.P., Reyes E., Tapia P. et al. Redefining micrometastasis in prostate cancer – a comparison of circulating prostate cells, bone marrow disseminated tumor cells and micrometastasis: Implications in determining local or systemic treatment for biochemical failure after radical prostatectomy. Int J Mol Med 2012;30(4): 896–904.35. Balic M., Williams A., Dandachi N., Cote R.J. Micrometastasis: detection methods and clinical importance. Cancer Biomark 2010;9(1–6):397–419.Balic M., Williams A., Dandachi N., Cote R.J. Micrometastasis: detection methods and clinical importance. Cancer Biomark 2010;9(1–6):397–419.36. Bork U., Grützmann R., Rahbari N.N. et al. Prognostic relevance of minimal residual disease in colorectal cancer. World J Gastroenterol 2014;20(30):10296–304.Bork U., Grützmann R., Rahbari N.N. et al. Prognostic relevance of minimal residual disease in colorectal cancer. World J Gastroenterol 2014;20(30):10296–304.37. Wang G., Wang S., Li Y. et al. Clinical study of disseminated tumor cells in bone marrow of patients with gastric cancer. Hepatogastroenterology 2013;60(122):273–6.Wang G., Wang S., Li Y. et al. Clinical study of disseminated tumor cells in bone marrow of patients with gastric cancer. Hepatogastroenterology 2013;60(122):273–6.38. Mohajeri G., Sanei M.H., Tabatabaee S.A. et al. Micrometastasis in non-small-cell lung cancer: Detection and staging. Ann Thorac Med 2012;7(3):149–52.Mohajeri G., Sanei M.H., Tabatabaee S.A. et al. Micrometastasis in non-small-cell lung cancer: Detection and staging. Ann Thorac Med 2012;7(3):149–52.39. Li X., Asmitananda T., Gao L. et al. Biomarkers in the lung cancer diagnosis: a clinical perspective. Neoplasma 2012;59(5):500–7.Li X., Asmitananda T., Gao L. et al. Biomarkers in the lung cancer diagnosis: a clinical perspective. Neoplasma 2012;59(5):500–7.40. Dragomir A., Moldoveanu E., Mihălţan F. Update regarding the role of biomarkers in early diagnosis of non-small cell bronchopulmonary cancer. Pneumologia 2011;60(1):9–13.Dragomir A., Moldoveanu E., Mihălţan F. Update regarding the role of biomarkers in early diagnosis of non-small cell bronchopulmonary cancer. Pneumologia 2011;60(1):9–13.41. Yovtchev Y.P., Minkov G.A., Petrov A.T. et al. Epithelial cells expressing cytokeratins-19 and bone marrow micrometastases in patients with breast cancer at the time of primary surgery: clinical outcome during long-term follow-up. Breast Cancer 2014;21(5): 590–7.Yovtchev Y.P., Minkov G.A., Petrov A.T. et al. Epithelial cells expressing cytokeratins-19 and bone marrow micrometastases in patients with breast cancer at the time of primary surgery: clinical outcome during long-term follow-up. Breast Cancer 2014;21(5): 590–7.42. Hartkopf A.D., Taran F.A., Wallwiener M. et al. Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients – results from a large single-centre analysis. Eur J Cancer 2014;50(15):2550–9.Hartkopf A.D., Taran F.A., Wallwiener M. et al. Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients – results from a large single-centre analysis. Eur J Cancer 2014;50(15):2550–9.43. Gebauer G., Fehm T., Merkle E. et al. Epithelial cells in bone marrow of breast cancer patients at time of primary surgery. Clinical outcome during long-term follow-up. J Clin Oncol 2001;19(16):3669–74.Gebauer G., Fehm T., Merkle E. et al. Epithelial cells in bone marrow of breast cancer patients at time of primary surgery. Clinical outcome during long-term follow-up. J Clin Oncol 2001;19(16):3669–74.44. Langer I., Guller U., Worni M. et al. Bone marrow micrometastases do not impact diseasefree and overall survival in early stage sentinel lymph node-negative breast cancer patients. Ann Surg Oncol 2014;21(2):401–7.Langer I., Guller U., Worni M. et al. Bone marrow micrometastases do not impact diseasefree and overall survival in early stage sentinel lymph node-negative breast cancer patients. Ann Surg Oncol 2014;21(2):401–7.45. Janni W., Rack B., Kasprowicz N. et al. DTCs in breast cancer: clinical research and practice. Recent Results Cancer Res 2012;195:173–8.Janni W., Rack B., Kasprowicz N. et al. DTCs in breast cancer: clinical research and practice. Recent Results Cancer Res 2012;195:173–8.